Abbott India

Mirae Asset Sharekhan is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 34,470 in its research report dated September 17, 2025.

Chartist Talks: Bank Nifty on track to hit 60,000 milestone before Diwali, bullish on these 4 stocks, says SBI Securities' Sudeep Shah

Backed by strong technical indicators and firm sectoral participation, Nifty now looks poised to extend its northward journey in the coming weeks and is likely to test the level of 25,800, followed by 26,100 in the short term, said SBI Securities' Sudeep Shah.

Stocks to Watch Today: Zydus Lifesciences, Tata Elxsi, Abbott India, ESAF Small Finance Bank, Siemens Energy, Aegis Vopak, IKS Health, Vodafone in focus on 19 June

Stocks to Watch, 19 June: Stocks like Siemens Energy India, HDFC Bank, Aavas Financiers, Vodafone Idea, Kirloskar Brothers, Andhra Paper, Hero MotoCorp, Aegis Logistics, Aegis Vopak Terminals, Zydus Lifesciences, Tata Elxsi, Abbott India, ESAF Small Finance Bank, and Inventurus Knowledge Solutions will be in focus on June 19.

Buy Abbott India; target of Rs 35,750: ICICI Securities

ICICI Securities is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 35,750 in its research report dated May 16, 2025.

Stocks to Watch Today: PB Fintech, Allied Blenders, LIC Housing, Bharti Airtel, Abbott India, Rail Vikas Nigam, Infosys, JSW Energy in focus on 16 May

Stocks to watch, 16 May: Stocks like Onesource Specialty Pharma,One 97 Communications Paytm,Industrial Investment Trust, Alkem Laboratories, Bajaj Auto, Godfrey Phillips India, Endurance Technologies, Bikaji Foods International,Godrej Industries, Bharti Airtel, Infosys, JSW Energy, LIC Housing Finance, and Allied Blenders and Distillers will be in focus on May 16.

Trade Spotlight: How should you trade Larsen & Toubro, Narayana Hrudayalaya, JSW Energy, Bajaj Finance, PFC, and others on March 4?

The market may attempt a bounce back considering the oversold conditions, but it is unlikely to sustain the same. Below are some trading ideas for the near term.

Buy Abbott India; target of Rs 32700: ICICI Securities

ICICI Securities is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 32700 in its research report dated February 06, 2025.

Nifty Pharma emerges as top sectoral gainer; US generics players could benefit from Trump's tariffs

Any tariffs on India or potential onshoring in US would be counterproductive, increasing the prices for US generics created by Indian pharma players.

Abbott India shares jump 6% after Q3 net profit jumps 16% to Rs 361 crore

The pharma company's revenue from operations rose 12 percent to Rs 1,614.28 crore in Q3 of the current financial year. The company had earlier reported revenue from operations at Rs 1,437.14 crore for Q3 of the previous financial year

Stock Radar: HDFC Bank, Indus Towers, Gravita India, HCC, Texmaco Rail, Nitco, Jungle Camps, Toss The Coin in focus on Tuesday

Stocks like Rail Vikas Nigam, Varun Beverages, Vedanta, Abbott India, Hindustan Construction Company, Gabriel Pet Straps, Everest Industries, RailTel Corporation of India, Wipro, Hitech Corporation, SRF, and GMR Airports Infrastructure will also be in focus on December 17.

Abbott India posts 15% rise in Q2 profit on strong demand, price hikes

Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said

Trade Spotlight: How should you trade Abbott India, NALCO, ITC, Vishnu Chemicals, Power Grid, and others on Tuesday?

The bearish sentiment is expected to continue, as the market traded well below all key moving averages (10-20-50-100 EMAs). Below are some trading ideas for the near term.

Buy Abbott India; target of Rs 32000: Sharekhan

Sharekhan is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 32000 in its research report dated August 08, 2024.

Buy Abbott India; target of Rs 30,540: Sharekhan

Sharekhan is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 30,540 in its research report dated May 09, 2024.

Abbott India shares surge 5% on strong Q4 results, record dividend payout

Over the last five years, Abbott India has seen its dividend payout outpace its profit growth. While net profit grew at a compounded rate of 22 percent between FY20 and FY24, the dividend per share (DPS) surged at a compound annual growth rate (CAGR) of 45 percent during the same period.

Abbott Q4 Results: Net profit rises 24% to Rs 287 crore, revenue up 7%

The company's revenue increased 7 percent to Rs 1,439 crore from Rs 1,343 crore in the year-ago period, Abbott India said on May 9.

Abbott India scale 52-week high after solid Q3 earnings

for Abbott India, strong demand in the quarter offset the adverse impact of pricing cap on certain drugs